NRG Oncology Joins the Caris Precision Oncology Alliance


Caris Life Sciences has announced that NRG Oncology (NRG), a National Cancer Institute (NCI) National Clinical Trials Network (NCTN) cooperative group, has joined the Caris Precision Oncology Alliance (POA).

The POA is a growing network of cancer centers and research consortia across the globe that collaborate to advance precision oncology and biomarker-driven research, with its members working together to establish standards of care for molecular testing through research to improve clinical outcomes for cancer patients. POA members are positioned to leverage Caris' AI bioinformatics and machine learning capabilities across the company's clinico-genomic database to enable research to improve clinical outcomes for cancer patients.

NRG Oncology is a non-profit National Cancer Institute (NCI) National Clinical Trials Network (NCTN) cooperative group founded in 2012 as a collaboration of research legacy groups including the National Surgical Adjuvant Breast and Bowel Project (NSABP), the Radiation Therapy Oncology Group (RTOG), and the Gynecologic Oncology Group (GOG). The organization designs and conducts practice-changing, multi-institutional clinical and translational research, with an emphasis on gender-specific malignancies, in an effort to improve the lives of those affected by cancer. The research led by NRG helps to disseminate study results that directly impact and inform clinical decision making and healthcare policy.

"NRG Oncology is proud to pursue a collaboration with the Caris Precision Oncology Alliance. We are confident that this partnership will enhance our common goals of advancing the use of molecular profiling in the evolution of practice changing clinical trials," stated Norman Wolmark, MD, NRG Oncology group chair.

"We are excited to welcome NRG into the Caris POA, as our research goals are aligned to leverage cutting-edge clinical trials and available biorepository specimens to improve the outcomes of all patients inflicted with cancer," said Chadi Nabhan, MD, MBA, FACP, chairman of the POA. "We are off to an amazing start as we work together on digitized pathology capabilities to identify molecular and cellular features associated with recurrence in breast cancer."

The Caris Precision Oncology Alliance includes 88 cancer centers, academic institutions, research consortia and healthcare systems. These institutions have early access to the database and artificial intelligence platform within Caris to establish evidence-based standards for cancer profiling and molecular testing in oncology. By leveraging the genomic, transcriptomic, and proteomic profiling available through Caris molecular profiling, Caris seeks to provide this network with the ability to prioritize therapeutic options and determine which clinical trial opportunities may benefit their patients. POA members are also able to integrate with a growing portfolio of biomarker-directed trials sponsored by biopharma. Additionally, POA member institutions have access to a clinico-genomic database, which includes matched molecular and clinical outcomes data from hundreds of thousands of cancer patients, covering over 1 million data points per patient.


The Caris Precision Oncology Alliance Welcomes NRG Oncology. (2023, August 14). Cision PR Newswire.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.